Taysha Gene Therapies, Inc. TSHA Depreciation
Depreciation at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s depreciation?
- Taysha Gene Therapies, Inc. (TSHA) reported depreciation of $295K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s depreciation changed year-over-year?
- Taysha Gene Therapies, Inc.'s depreciation increased by 4.2% year-over-year, from $283K to $295K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s depreciation?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s depreciation has grown at a 19.8% compound annual growth rate (CAGR), from $526K to $1.08M.